In glioma, experimentation with SFRP1 as an inhibitor of the WNT pathway led to the discovery of its role as a direct target of miR-32, which is highly upregulated in invasive glioma cells (Delic et al., 2014). This evidence concerns the gene SFRP1 and central nervous system cancer.